The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that
protect against severe disease and preferably drive herd immunity. Regulators in numerous …

Immunization is a cornerstone of public health policy and is demonstrably highly cost-
effective when used to protect child health. Although it could be argued that immunology has …

The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
has caused more than 1 million deaths in the first 6 months of the pandemic and huge …

Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control …

On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …

Summary Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for
emergency use by the UK regulatory authority, Medicines and Healthcare products …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background Older adults (aged≥ 70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

The global supply of COVID-19 vaccines remains limited. An understanding of the immune
response that is predictive of protection could facilitate rapid licensure of new vaccines. Data …